Category: by author

A Cancer Cell mega-correction for highly cited researcher who retracted paper earlier this year

cancer cell 9-13MIT’s Robert Weinberg, a leading cancer researcher who retracted a Cancer Cell paper earlier this year for “inappropriate presentation” of figures, has corrected a different paper in the same journal.

Here’s the correction for “Species- and Cell Type-Specific Requirements for Cellular Transformation:”

We were apprised recently of errors made in the assembly of Figures 2B, 3A, 4A, 4B, and 5G, resulting in the incorporation of incorrect representative images in these figures. These errors occurred during the electronic assembly and have no bearing on the conclusions of the study. The corrected figures are shown below. The authors apologize for any possible confusion this might have caused.

Here’s the original Figure 2 and caption, followed by the new version (read all the way to the end of the post for more details on how this came to light): Continue reading A Cancer Cell mega-correction for highly cited researcher who retracted paper earlier this year

What happened to Joachim Boldt’s 88 papers that were supposed to be retracted?

a&amisconductcoverCHICAGO — Almost two years after editors at 18 journals agreed in March 2011 to retract 88 of former retraction record holder Joachim Boldt’s papers, 10% of them hadn’t been retracted.

That’s what Nadia Elia, Liz Wager, and Martin Tramer reported here Sunday in an abstract at the Seventh International Congress on Peer Review and Biomedical Publication. Elia and Tramer are editors at the European Journal of Anaesthesiology, while Wager is former chair of the Committee on Publication Ethics (COPE).

As of January 2013, nine of the papers hadn’t been retracted, Tramer said, while only five — all in one journal — had completely followed COPE guidelines, with adequate retraction notices, made freely available, along with  PDFs properly marked “Retracted.” From the abstract (see page 18): Continue reading What happened to Joachim Boldt’s 88 papers that were supposed to be retracted?

Diederik Stapel speaks

stapel_npcDiederik Stapel, the social psychologist who has now retracted 54 papers, recently spoke as part of the TEDx Braintrain, which took place on a trip from Maastricht to Amsterdam. Among other things, he says he lost his moral compass, but that it’s back.

Here’s the talk, which lasts 17 minutes: Continue reading Diederik Stapel speaks

Are US behavioral science researchers more likely to exaggerate their results?

Daniele Fanelli
Daniele Fanelli

When Retraction Watch readers think of problematic psychology research, their minds might naturally turn to Diederik Stapel, who now has 54 retractions under his belt. Dirk Smeesters might also tickle the neurons.

But a look at our psychology category shows that psychology retractions are an international phenomenon. (Remember Marc Hauser?) And a new paper in the Proceedings of the National Academy of Sciences (PNAS) suggests that it’s behavioral science researchers in the U.S. who are more likely to exaggerate or cherry-pick their findings.

For the new paper, Daniele Fanelli — whose 2009 paper in PLoS ONE contains some of the best data on the prevalence of misconduct — teamed up with John Ioannidis, well known for his work on “why most published research findings are false.” They looked at Continue reading Are US behavioral science researchers more likely to exaggerate their results?

Author with six recent corrections retracts JBC paper questioned on PubPeer

jbc 8-23-13Rakesh Kumar, a professor at the George Washington University, has retracted a paper in the Journal of Biological Chemistry (JBC) that was recently questioned on PubPeer.

Here are Peer1’s comments from PubPeer about the paper, “Mechanism of MTA1 Protein Overexpression-linked Invasion:” Continue reading Author with six recent corrections retracts JBC paper questioned on PubPeer

Retraction appears for Harvard scientist who had two mega-corrections last year

molecular cellSam Lee, a Harvard biologist who had two mega-corrections published last year, has retracted a paper in Molecular Cell because some of the figures were “inappropriately assembled.”

Here’s the notice for “GAMT, a p53-Inducible Modulator of Apoptosis, Is Critical for the Adaptive Response to Nutrient Stress:” Continue reading Retraction appears for Harvard scientist who had two mega-corrections last year

Journal to feature special issue on scientific misconduct, seeks submissions

steen
Grant Steen

It would be difficult to read the recent scientific literature on retractions and miss Grant Steen’s contributions. Retraction Watch readers are no doubt familiar with his work by this point, and if they’re not, we’d recommend spending some time with it. The journal Publications — an MDPI title — has asked him to guest-edit a special issue on scientific misconduct, and Steen asked us to get the word out, so we’re happy to post this introduction from him: Continue reading Journal to feature special issue on scientific misconduct, seeks submissions

Aussie university halts trials of skin cancer drug whose developer has four retractions

khachigian
Khachigian

An Australian university has put a hold on trials of an experimental drug for skin cancer whose main developer has been dogged by charges of research misconduct for several years.

The Australian Broadcasting Corporation is reporting that the University of New South Wales has suspended trials of the drug, DZ13, while it investigates the work of Levon Khachigian, who is leading the studies.

According to the news organization, Khachigian and his group were cleared by the school in two prior inquiries. However, additional accusations of misconduct — specifically involving image manipulation and misuse — prompted a third investigation.

We’ve found four retractions of Khachigian’s studies, from the Journal of Biological Chemistry and Biochemical and Biophysical Research Communications, between 2009 and 2010 (before the launch of Retraction Watch).

They are: Continue reading Aussie university halts trials of skin cancer drug whose developer has four retractions

Penkowa notches fourth retraction, in Experimental Neurology

exp neuroMilena Penkowa, the Danish neuroscientist who resigned from the University of Copenhagen in December 2010 amid suspicions of misconduct, has had another paper retracted.

The new retraction appears in Experimental Neurology. Here’s the notice for “M-CSF deficiency leads to reduced metallothioneins I and II expression and increased tissue damage in the brain stem after 6-aminonicotinamide treatment”: Continue reading Penkowa notches fourth retraction, in Experimental Neurology

University, funding agency clear researcher Rui Curi of fraud charges

Rui Curi
Rui Curi

The University of São Paulo and Brazil’s National Council of Technological and Scientific Development funding agency (CNPq) have cleared a researcher of fraud following a six-month investigation.

The CNPq’s Commission on Integrity in Scientific Activity noted, however, that “there was failure to exercise rigor in the conduct and dissemination of results [in Rui Curi’s work], essential to quality research.” Continue reading University, funding agency clear researcher Rui Curi of fraud charges